Nov 14, 2007 by Brian LawlerNeurochem's Crazy ChoiceNeurochem chooses a risky path for its lead drug candidate.
Nov 14, 2007 by Brian LawlerGenzyme Zigs, Shares ZagGenzyme gets downbeat news on a lead drug, but no one seems to notice.
Nov 14, 2007 by Brian LawlerBusy Times Ahead for CardiomeKeep an eye on vernakalant and Cardiome over the next three months.
Nov 13, 2007 by Brian LawlerNektar's New Old DrugPfizer returns control of a drug that just wouldn't sell.
Nov 12, 2007 by Brian LawlerVanda Gets Set for a Busy 2008But prepare for the FDA to toss a snag into the process.
Nov 9, 2007 by Brian LawlerGPC RegroupsThe pharma updates investors following a setback on its lead drug.
Nov 9, 2007 by Brian LawlerA Gauntlet for King PharmaceuticalsIt faces more competition for its top drugs, but the cash keeps rolling in.
Nov 9, 2007 by Brian LawlerCephalon Wheels and DealsThe drugmaker releases its third-quarter financial results.
Nov 8, 2007 by Brian LawlerIdenix Reels Itself InHepatitis-treatment progress takes a step back in Q3.
Nov 7, 2007 by Brian LawlerFollowing Up on ExelixisExelixis updates investors on the progress with its pipeline.
Nov 6, 2007 by Brian LawlerNo Surprise That Vertex Has CompetitionDid shares of Vertex slump on competition concerns?
Nov 6, 2007 by Brian LawlerIt's All About VELCADE at MillenniumMillennium announces a strong quarter of financial results.
Nov 6, 2007 by Brian LawlerWill BioMarin Manage Its Money?The future looks good, but the potential for acquisitions is always a concern.
Nov 5, 2007 by Brian LawlerEncysive in a No-Win SituationIt needs help to get its lead drug onto the U.S. market in time to turn its financials around.
